Prothena and Roche present positive Parkinson's and Alzheimer's data, which biotech stocks could benefit most from these developments?

``` The deep research logic is organized as follows: Okay, let's tackle this question. The user is asking which biotech stocks could benefit most from Prothena and Roche presenting positive data on Parkinson's and Alzheimer's. First, I need to look through the provided references to find relevant information about these companies and their partnerships or developments in these diseases. Starting with Prothena (PRTA), the references mention that they presented data on prasinezumab for Parkinson's and BMS-986446 for Alzheimer's at the AD/PD 2026 conference. The data showed sustained effects in slowing Parkinson's progression and targeting tau proteins in Alzheimer's. Roche is involved with prasinezumab, and they also presented on integrating blood biomarkers for Alzheimer's diagnosis. Next, looking at the list of biotech companies from the 2026 query (Reference 15), Prothena isn't listed, but other companies like Neurocrine Biosciences (NBIX) and Immunis (IMUN) are. Immunis has a deal for a Parkinson's treatment (KORA) targeting dyskinesia, which is a common side effect of current treatments. AC Immune (ACIU) is mentioned in several references, including their Phase 2 data for ACI-7104 in Parkinson's and collaboration with Janssen for Alzheimer's. They also faced a pause in an Alzheimer's trial but the reason isn't clear yet. Other companies like Arvinas (ARVN) have positive Phase 1 data for ARV-102 targeting LRRK2 in Parkinson's. Biogen (BIIB) is involved in Alzheimer's with their partnership with AC Immune. The user's profile shows interest in NASDAQ stocks, so focusing on those like ACIU, PRTA, IMUN, and ARVN makes sense. I need to structure the answer by highlighting the key companies, their specific developments, and why they might benefit. Also, include a table of the top picks with reasons. Make sure to cite the references properly and include the visualization for the query results. The user prefers a mix of technical analysis and fundamental data, so mentioning stock performance and recent news could be relevant. Wait, the user's profile mentions a focus on NASDAQ, so check which companies are listed there. Prothena is on NASDAQ (PRTA), Immunis isn't listed in the provided data, but AC Immune is (ACIU). Arvinas is also on NASDAQ (ARVN). Neurocrine (NBIX) is another NASDAQ stock. Need to ensure the answer aligns with the user's interest in these indices. Also, the user likes technical analysis, so maybe include recent stock trends or analyst ratings if available. However, the references don't provide detailed stock performance data beyond the query results. The query results for ACIU show a bullish trend, which could be a point to mention. Putting it all together, the answer should start with a conclusion, then detail each company's role, supported by the references, and end with a table of top picks. Make sure to use the correct citations and include the visualization for the query results as specified. ``` ### 🌟 **Conclusion** Prothena (PRTA) and Roche’s recent presentations at the AD/PD 2026 conference highlight significant progress in Parkinson’s and Alzheimer’s treatments, particularly in targeting alpha-synuclein, tau proteins, and neuroinflammation. Biotech stocks poised to benefit most include **AC Immune (ACIU)**, **Prothena (PRTA)**, **Immunis (IMUN)**, and **Arvinas (ARVN)**, due to their advanced pipelines, strategic partnerships, and focus on disease-modifying therapies. Below is a detailed analysis of these companies and their potential upside. --- ### 🧠 **Key Companies and Their Developments** #### 1. **AC Immune (ACIU)** - **Pipeline**: - **ACI-7104**: Phase 2 active immunotherapy targeting alpha-synuclein in early Parkinson’s, showing strong immunogenicity and biomarker engagement . - **ACI-35.030**: Tau-targeting immunotherapy for Alzheimer’s, advancing to Phase 2b with Janssen . - **Rationale**: AC Immune’s dual focus on Parkinson’s and Alzheimer’s aligns with Prothena’s and Roche’s protein dysregulation strategies. Recent interim data suggest potential disease-modifying effects . - **Risk**: Pause in Alzheimer’s trial (ACI-35.030) due to unclear reasons . #### 2. **Prothena (PRTA)** - **Pipeline**: - **Prasinezumab**: Open-label extension data show sustained slowing of Parkinson’s progression over 5 years . - **BMS-986446**: Tau-targeting antibody for Alzheimer’s, activating microglia for tau clearance . - **Rationale**: Prothena’s late-stage pipeline and partnerships with Roche and Bristol-Myers Squibb (BMS) position it as a leader in neurodegenerative therapies . - **Risk**: Recent stock price volatility (bearish trend) . #### 3. **Immunis (IMUN)** - **Pipeline**: - **IMM02-KORA (KORA)**: Phase 1 IND filed for L-DOPA-induced dyskinesia in Parkinson’s, supported by preclinical data . - **Rationale**: Focus on a critical unmet need (dyskinesia) complements Prothena’s and Roche’s disease-modifying approaches . - **Risk**: Early-stage development with no clinical data yet . #### 4. **Arvinas (ARVN)** - **Pipeline**: - **ARV-102**: Phase 1 data show >50% LRRK2 degradation in Parkinson’s patients, reducing neuroinflammatory biomarkers . - **Rationale**: PROTAC-based degradation technology offers a novel mechanism for neurodegenerative diseases . - **Risk**: Limited commercialization history for PROTACs . --- ### 📊 **Top Biotech Stocks to Watch** | **Ticker** | **Company** | **Focus** | **Key Catalyst** | **Risks** | |------------|-----------------------|--------------------------------------|-------------------------------------------------------|------------------------------------------------| | **ACIU** | AC Immune | Alpha-synuclein (Parkinson’s), Tau (Alzheimer’s) | Phase 2 data for ACI-7104; Janssen partnership | Alzheimer’s trial pause, high R&D costs | | **PRTA** | Prothena | Prasinezumab (Parkinson’s), Tau (Alzheimer’s) | Open-label extension data; Roche partnership | Stock volatility, late-stage trial risks | | **IMUN** | Immunis | Dyskinesia (Parkinson’s) | Phase 1 IND filing; Toray licensing agreement | Early-stage pipeline, no clinical data yet | | **ARVN** | Arvinas | LRRK2 degradation (Parkinson’s) | Phase 1 data for ARV-102; neuroinflammation focus | PROTAC commercialization risks, high valuations | --- ### 🌟 **Final Takeaway** The convergence of protein-targeting therapies (e.g., anti-alpha-synuclein, tau immunotherapies) positions **AC Immune (ACIU)** and **Prothena (PRTA)** as top picks for long-term growth. **Immunis (IMUN)** and **Arvinas (ARVN)** offer high-risk, high-reward opportunities in niche areas like dyskinesia and LRRK2 degradation. Investors should balance these stocks with a medium-term horizon, monitoring clinical trial updates and partnership news closely. list of biotech companies developing Parkinson's disease treatments 2026 |code|market_code|stock code|stock name|Last Price|Last Change|Theme|Inclusion Reason|GICS Industry|GICS Sub-Industry| |---|---|---|---|---|---|---|---|---|---| |ALNY|185|ALNY.O|Alnylam Pharmaceuticals|312.17|0.343941|||Pharmaceuticals|Pharmaceuticals| |SRPT|185|SRPT.O|Sarepta|16.69|0.24023999999999998|||Pharmaceuticals|Pharmaceuticals| |EXEL|185|EXEL.O|Exelixis|41.27|0.024237|||Pharmaceuticals|Pharmaceuticals| |BHVN|169|BHVN.N|Biohaven|8.93|-0.334821|||Pharmaceuticals|Pharmaceuticals| |NVO|169|NVO.N|Novo Nordisk|36.53|-1.483279|||Pharmaceuticals|Pharmaceuticals| |NBIX|185|NBIX.O|Neurocrine Biosciences|127.68|-1.55744|||Pharmaceuticals|Pharmaceuticals| |PFE|169|PFE.N|Pfizer|26.97|-1.605254|||Pharmaceuticals|Pharmaceuticals| |BMRN|185|BMRN.O|Biomarin|54.13|-1.635472|||Pharmaceuticals|Pharmaceuticals| |GMAB|185|GMAB.O|Genmab|25.1|-2.448504|||Pharmaceuticals|Pharmaceuticals| |LEGN|185|LEGN.O|Legend Biotech|17.41|-2.574147|||Pharmaceuticals|Pharmaceuticals|